Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Incretin Effect in Patients With Chronic Pancreatitis
This study has been completed.
Sponsors and Collaborators: University Hospital, Gentofte, Copenhagen
University of Copenhagen
Information provided by: University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier: NCT00638573
  Purpose

The phenomenon that oral glucose elicits a higher insulin response than does intravenous (iv) glucose, even at identical plasma glucose (PG) profiles (isoglycemia), is called the incretin effect. In type 2 diabetes mellitus (T2DM) the incretin effect has been shown to be markedly reduced or even abolished. It is not known whether the reduced incretin effect in T2DM is a primary event leading to T2DM or if it is merely a consequence of the diabetic state. To answer this question we plan to estimate the incretin effect in 8 patients with secondary diabetes mellitus (DM) to chronic pancreatitis (CP) and compare it to the incretin effect of 8 patients with CP and normal glucose tolerance (NGT). Eight patients with T2DM and 8 healthy control subjects are studied for comparison. The incretin effect is measured by a 50-g oral glucose tolerance test and an isoglycemic intravenous glucose infusion.


Condition
Chronic Pancreatitis
Type 2 Diabetes Mellitus

MedlinePlus related topics: Diabetes
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: The Incretin Effect in Patients With Chronic Pancreatitis With and Without Secondary Diabetes Mellitus

Further study details as provided by University Hospital, Gentofte, Copenhagen:

Estimated Enrollment: 24
Study Start Date: January 2006
Estimated Study Completion Date: July 2006
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Diagnosis of chronic pancreatitis with secondary diabetes mellitus
  • Diagnosis of chronic pancreatitis with normal glucose tolerance
  • Diagnosis of type 2 diabetes
  • Normal level of hemoglobin
  • Normal level of se-creatinine

Exclusion Criteria:

  • GAD-65 autoantibodies
  • ICA autoantibodies
  • Albuminuria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00638573

Locations
Denmark, Copenhagen County
Gentofte University Hospital
Hellerup, Copenhagen County, Denmark, 2900
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
University of Copenhagen
Investigators
Principal Investigator: Filip K Knop, MD University of Copenhagen
Study Director: Jens J Holst, MD DMSc University of Copenhagen
Study Director: Thure Krarup, MD DMSc Gentofte University Hospital
  More Information

Study ID Numbers: KA04034
Study First Received: March 12, 2008
Last Updated: March 12, 2008
ClinicalTrials.gov Identifier: NCT00638573  
Health Authority: Denmark: National Board of Health

Study placed in the following topic categories:
Digestive System Diseases
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Neoplasm Metastasis
Pancreatic Diseases
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Pancreatitis
Pancreatitis, Chronic

ClinicalTrials.gov processed this record on January 16, 2009